[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polymyalgia-rheumatica\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polymyalgia-rheumatica":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,40,68,95,125,165,190,217,254,275],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100614947","phase-4-sarilumab-efficacy-and-safety-in-adults-with-early-polymyalgia-rheumatica-100614947",false,"NCT07286214","Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica","A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Each of Two Dose Levels of Sarilumab in Adults With Early Polymyalgia Rheumatica","Inclusion Criteria:\n\n* Adults ≥50 years with polymyalgia rheumatica according to the EULAR\u002FACR classification criteria\n* Meet criteria for newly diagnosed PMR (received ≤6 weeks of corticosteroids prior to randomization) or for early relapsing PMR (initiated corticosteroid treatment within last year, treated with prednisone ≥10 mg\u002Fday for ≥ 8 weeks, and experienced flare within prior 12 weeks while receiving ≥5 mg\u002Fd prednisone)\n* Participants must be willing and able to take prednisone of 15 mg\u002Fday at randomization\n* Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies\n\nExclusion Criteria:\n\n* Diagnosis of Giant Cell Arteritis (GCA)\n* Concurrent rheumatoid arthritis, inflammatory arthritis, connective tissue diseases, fibromyalgia\n* Inadequately treated hypothyroidism\n* Exclusion related to tuberculosis (TB), invasive opportunistic infections, recurrent or persistent infections including hepatitis B, C or HIV, recurrent herpes zoster or active herpes zoster\n* Patients with uncontrolled diabetes mellitus (HbA1c ≥9%)\n* Immunosuppressive therapies including systemic corticosteroids\n* Malignancy\n* Organ transplant recipient\n\nThe above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.","ALL","50 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This is a randomized, double-blind, placebo-controlled, parallel-group, Phase 4, 3-group study to assess whether treatment with sarilumab at either 150 mg q2w (once every two weeks) or at 200 mg q2w, each given with a 52-week prednisone taper, is superior to placebo given with a 52-week prednisone taper in participants with early polymyalgia rheumatica (PMR) and to determine the safety and tolerability of the sarilumab regimens.\n\nThe study will consist of the following visits:\n\nVisit 1 (D-42 to D-1): Screening, Visit 2 (D1): Baseline, randomization, first study drug administration, Visit 3 to 12 (Week 2 to Week 52): Treatment period, Visit 13 (Week 52): End of Treatment (EOT) visit, Visit 14 (Week 58): End of Study (EOS) visit.",[26],"Polymyalgia Rheumatica","RECRUITING","2026-06-19",{"date":30,"type":31},"2026-06-23","ACTUAL",{"date":33,"type":31},"2026-05-12",{"date":35,"type":20},"2029-07-16",{"name":37,"class":38},"Sanofi","INDUSTRY",14,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100603103","justification-of-the-initial-diagnosis-and-evaluation-of-the-overall-evolution-of-a-cohort-of-recent-polymyalgia-rheumatica-jadore-100603103","NCT07132164","Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica (JADORE)","Justification of the Initial Diagnosis and Evaluation of the Overall Evolution of a Cohort of Recent Polymyalgia Rheumatica","JADORE","Inclusion Criteria:\n\n* Age greater than or equal to 50, with no upper age limit\n* Inflammatory shoulder +\u002F- hip pain\n* Abnormal CRP (≥10mg\u002FL)\n* Patients for whom the referring rheumatologist accepts the diagnosis of PPR after carrying out the assessment corresponding to his or her current practice\n* Patients for whom the referring rheumatologist has indicated that corticosteroid therapy should be started in the strict context of PPR or as background treatment for PPR.\n* Symptoms have progressed for 24 weeks or less\n\nExclusion Criteria:\n\n* Presence, at the time of diagnosis, of symptoms and\u002For signs suggesting a diagnosis of associated giant cell arteritis\n* Immuno-induced PPR\n* Patients receiving immunosuppressive treatment with methotrexate or immunotherapy targeting interleukin-6 at inclusion.\n* Patients who have received corticosteroid therapy for more than 30 days or a cumulative dose of more than 500 mg of Prednisone equivalent in the month preceding the screening visit.\n* Patients with another chronic condition requiring long-term corticosteroid therapy or repeated courses of corticosteroids.\n* Patients not affiliated to a social security scheme\n* Patients unable to consent or unable or unwilling to complete their corticosteroid dose monitoring record.\n* Pregnancy\n* Patients under guardianship, curatorship or safeguard of justice",{"count":49,"type":20},400,"OBSERVATIONAL","Pseudo-rheumatoid arthritis (PRA) is a common inflammatory rheumatic disease of the elderly, characterized by inflammatory shoulder and\u002For hip pain. Its routine diagnosis is based on a number of clinical criteria, the presence of a biological inflammatory syndrome and the elimination of the main differential diagnoses. It is sometimes referred to as PPR syndrome, since around 25% of initial diagnoses are not confirmed at one year's follow-up (PPR syndrome revealing rheumatoid arthritis, microcrystalline rheumatism, etc.). Diagnosis may be facilitated by ultrasound scans of the shoulders and hips, which may show characteristic inflammatory lesions, or by PET scans when there is a marked deterioration in general condition or other clinical atypia. PPR may be associated at the outset, or it may evolve into the rarer vasculitis of the elderly, giant cell arteritis (GCA), a condition that can lead to severe and irreversible neurological vascular damage if not treated early.\n\nProlonged, moderate-dose corticosteroid therapy is the cornerstone of PPR treatment, although new treatments are in the process of obtaining marketing authorization to enable cortisone sparing. Anti-IL-6 agents, and in particular Tocilizumab, have demonstrated their efficacy in recent cortico-dependent PPR, Sarilumab has obtained marketing authorization for cortico-dependent PPR in the USA in 2023, and other therapeutic classes are currently being evaluated in this situation. Recommendations, including those of ACR\u002FEULAR in 2015, advise a strategy of initiating corticosteroid therapy at a moderate dose, with a dosage of between 12.5 and 25 mg prednisone equivalent per day, and gradually tapering off with the aim of reaching a dosage of 10 mg prednisone equivalent per day at week 8, to achieve complete weaning at 12 months. However, on the one hand, these recommendations are not based on clinical trials and, on the other, the main comorbidities associated with PPR are related to this long-term corticosteroid therapy. Lastly, we know that around 50% of patients do not follow this tapering-off protocol, with either relapses (estimated at 50% during tapering) or the impossibility for around 25% of patients to stop corticosteroid therapy. However, there are currently no predictive factors for the evolution of PPR.\n\nPPR activity can be measured either using a validated score, the DAS-PPR, or according to the opinion of the rheumatologist. Good progression of rheumatoid arthritis is characterized by a low activity score (DAS-PPR\\\u003C10) and, wherever possible, discontinuation of treatment within one year, as recommended by international experts.\n\nThe main objective of this cohort is therefore to evaluate the percentage of patients with low-activity PPR (DAS-PPR\\\u003C10) and no treatment at 12 months.\n\nSecondary objectives will concern the initial phenotypic and evolutionary description of PPR (complete initial phenotypic characteristics, including some exploratory ones (imaging, biology, immunology, genetics, microbiota, avatars). The evolution of the disease, with the percentage of relapses during the decline or distant relapses, percentage of association with ACG, mortality rate, as well as the prognostic factors of these different evolutionary forms. A description of the disease-modifying treatments used (corticosteroid therapy and its decline, other immunomodulators), as well as a record of the complications presented by patients (development of ACG, corticosteroid toxicity, sarcopenia, osteoporosis fractures, diverticular perforation). Finally, many pathologies can clinically and biologically mimic PPR, leading to erroneous prescriptions of glucocorticoids for prolonged periods, and sometimes a delay in the diagnosis of serious conditions. These classic differential diagnoses will be investigated according to the clinical context and the clinician's judgement, and the diagnostic value of tests such as joint ultrasound, PET scans and biomarkers can be assessed.\n\nWith regard to patient follow-up, if an alternative diagnosis is identified immediately after the completion of additional examinations, the patient is no longer followed up in the study, and the alternative diagnosis is noted by the investigator. For patients for whom the investigator's conviction concerning the diagnosis of PPR remains above 50%, as at inclusion, follow-up in the study is continued. At one year's follow-up, if an alternative diagnosis has been made, this is collected and the patient is no longer followed up in the cohort. Follow-up for other patients then continues for 5 years. Deterministic matching to the SNDS will be performed for each patient included.\n\nTo date, there is no French prospective cohort dedicated to the follow-up of patients with a recent form of PPR, as has been done for rheumatoid arthritis, spondyloarthritis and psoriatic arthritis. The creation of such a cohort will improve our knowledge of this pathology, in terms of both pathophysiology and routine management.",[26,53],"Inflammatory Rheumatism",[55],"polymyalgia Rheumatica","NOT_YET_RECRUITING","2026-06-05",{"date":59,"type":31},"2026-06-08",{"date":61,"type":20},"2026-07-01",{"date":63,"type":20},"2035-07-01",{"name":65,"class":66},"University Hospital, Brest","OTHER",30,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100565819","a-qualitative-assessment-of-the-severity-and-impact-of-rheumatic-immune-related-adverse-events-following-immune-checkpoint-inhibitor-immunotherapy-100565819","NCT06647134","A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy","Inclusion Criteria\n\nThe criteria are:\n\n* Patients aged 18 years and above\n* English (conversational level) speaking, with the ability to give informed consent\n* Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy\n\nExclusion Criteria\n\n* Acutely life-threatening or worsening cancer\n* Hearing impairment functionally limiting participation in verbal interview","18 Years",{"count":76,"type":20},20,"To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.",[79,26,80],"Arthritis","Immune Checkpoint Inhibitors",[82,83,84],"arthritis","polymyalgia rheumatica","immune related adverse events","2026-04-10",{"date":87,"type":31},"2026-04-13",{"date":89,"type":31},"2024-09-11",{"date":91,"type":20},"2028-03-31",{"name":93,"class":66},"M.D. Anderson Cancer Center",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":124},"100472738","phase-4-effect-of-supplemental-hydrocortisone-during-stress-in-prednisolone-induced-adrenal-insufficiency-100472738","NCT05435781","Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency","RESCUE - Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency; A Multicentre, Randomised, Double Blinded, Placebo-controlled Clinical Trial on Health-related Quality of Life in Patients With Polymyalgia Rheumatica\u002FGiant Cell Arteritis Receiving Ongoing Low-dose Prednisolone Treatment.","RESCUE","Inclusion Criteria:\n\n* Age ≥ 50 years\n* Women must be postmenopausal (FSH is measured at the screening visit)\n* A diagnosis of PMR\u002FGCA, or both conditions combined.\n* Treatment with prednisolone ≥12 weeks\n* Ongoing prednisolone treatment, with current daily prednisolone dose \\> 0 mg and ≤5 mg. The dose must have been ≤5 mg for minimum 2 weeks at the time of the screening visit.\n\nExclusion Criteria:\n\n* Known primary or secondary adrenal insufficiency\n* Known Cushing's Syndrome\n* Known allergy towards study medication ingredients\n* Severe comorbidity: Heart failure (New York Heart Association class IV); Kidney failure with an estimated glomerular filtration rate \\\u003C30 mL\u002Fmin (Chronic kidney disease stage 4-5); Liver disease in the form of cirrhosis; Active cancer; Known severe immune deficiency; A history of psychiatric disease requiring treatment by a psychiatric department (for affective disorders only if within the last year before study entry)\n* Alcohol consumption \\>21 units per week\n* Planned major surgery during the study period at study entry.\n* Use of drugs that interfere with cortisol metabolism\u002Fmeasurements: Systemic oestrogen treatment (discontinued \\\u003C 1 month before inclusion), Treatment with strong CYP3A4 inhibitors or inducers, Use of other glucocorticoid formulations (Inhaled corticosteroids, intraarticular or intramuscular injections, steroid creams European steroid group IV-V used in the genital area. Note: Permitted glucocorticoid formulations: Eye-drops, nasal spray, glucocorticoid creams European steroid group I-III, and European steroid group IV-V used in the non-genital area only.)\n* Inability to provide written informed consent.",{"count":104,"type":20},250,[23],"In this double-blinded randomised placebo-controlled clinical trial, the aim is to determine the effect of supplemental hydrocortisone compared with placebo during mild to moderate physical or mental stress on health related quality of life in patients with polymyalgia rheumatica (PMR)\u002Fgiant cell arteritis (GCA) on ongoing low-dose prednisolone diagnosed with glucocorticoid-induced adrenal insufficiency. The main emphasis is on fatigue (primary outcome) and daily variation hereof during periods of stress.",[108,26,109],"Adrenal Insufficiency","Giant Cell Arteritis",[111,112,113,114],"Glucocorticoid-induced adrenal insufficiency","Prednisolone","Glucocorticoids","Hypothalamic-pituitary-adrenal axis","2026-03-12",{"date":117,"type":31},"2026-03-16",{"date":119,"type":31},"2022-06-07",{"date":121,"type":20},"2028-03-01",{"name":123,"class":66},"Marianne Christina Klose",3,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":131,"sex":16,"minAge":74,"maxAge":132,"enrollmentInfo":133,"targetDuration":135,"studyType":50,"phases":4,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":94},"100393366","rheumatology-patient-registry-and-biorepository-100393366","NCT04402086","Rheumatology Patient Registry and Biorepository","Inclusion Criteria for Rheumatology Patients:\n\n* Patients ≥18 years old with a diagnosis of a rheumatic autoimmune disease including, but not limited to: adult onset Still's disease, ankylosing spondylitis, antiphospholipid syndrome, Behcet's disease, dermatomyositis, giant cell arteritis, mixed connective tissue disease, polymyalgia rheumatica, polymyositis, psoriatic arthritis, reactive arthritis, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome, systemic lupus erythematosus, undifferentiated connective tissue disease and vasculitis.\n* Receiving clinical care at Yale Rheumatology clinics\n\nExclusion Criteria for Rheumatology Patients:\n\n* Unable to provide informed consent\n* No patients will be excluded based on gender or ethnicity or pregnancy status.\n* Women who are currently pregnant will need to wait to donate a skin biopsy until after they deliver.\n* Patients allergic to lidocaine or epinephrine or have a history of impaired wound healing will not be able to donate a skin biopsy.\n\nInclusion Criteria for Healthy Volunteers:\n\n* Age ≥ 18 years old\n* No chronic skin conditions\n* No diagnosis of a rheumatic autoimmune disease (e.g., lupus, rheumatoid arthritis)\n* Normal BMI\n\nExclusion Criteria for Healthy Volunteers:\n\n* Unable to provide informed consent.\n* Currently pregnant or nursing unless the study goal is to study pregnant or nursing woman.\n* Allergies to lidocaine or epinephrine (skin biopsies).\n* A history of impaired wound healing (skin biopsies).",true,"99 Years",{"count":134,"type":20},5000,"10 Years","To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.",[138,139,140,141,142,143,144,145,146,147,109,148,149,26,150,151,152,153,154,155],"Rheumatic Diseases","Adult Onset Still Disease","Ankylosing Spondylitis","Psoriatic Arthritis","Reactive Arthritis","Antiphospholipid Syndrome","Systemic Lupus Erythematosus","Behcet Disease","Dermatomyositis","Polymyositis","Lyme Disease","Mixed Connective Tissue Disease","Rheumatoid Arthritis","Sarcoidosis","Systemic Sclerosis","Scleroderma","Sjogren's Syndrome","Undifferentiated Connective Tissue Diseases","2026-02-11",{"date":158,"type":31},"2026-02-13",{"date":160,"type":31},"2020-08-04",{"date":162,"type":20},"2030-06-01",{"name":164,"class":66},"Yale University",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":174,"conditions":175,"keywords":178,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100623272","study-of-the-association-between-sacroiliitisaxial-spondylarthritis-and-giant-cell-arteritis-polymyalgia-rheumatica-100623272","NCT07394478","Study of the Association Between Sacroiliitis\u002FAxial Spondylarthritis and Giant Cell Arteritis\u002F Polymyalgia Rheumatica","Study of the Association Between Sacroiliitis\u002FAxial Spondylarthritis and Giant Cell Arteritis\u002F Polymyalgia Rheumatica: A Case-control Observational Study","SAGE PPR","Inclusion Criteria:\n\n* Experimental group: Adult patient with spondylitis associated with GCA or PMR Control group: Adult patient with GCA or PMR\n\nExclusion Criteria:\n\n* Refusal to participate\n* Positive anti CCP",{"count":5,"type":20},"The purpose of the study is to recruit as many patients as possible presenting with sacroiliitis or authentic axial spondylarthritis and giant cell arteritis. The investigators will also be interested in the association of spondylarthritis and polymyalgia rheumatica given the continuum between these two pathologies. The aim is to investigate whether there is an association between giant cell arteritis and spondylarthritis or polymyalgia rheumatica and spondylarthritis.",[176,177,26],"Giant Cell Arteritis (GCA)","Spondylarthritis",[176,177,179],"Polymyalgia rheumatica","2026-02-03",{"date":182,"type":31},"2026-02-06",{"date":184,"type":20},"2026-02-01",{"date":186,"type":20},"2026-06-30",{"name":188,"class":66},"Hôpital NOVO",2,{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":21,"phases":201,"briefSummary":203,"conditions":204,"keywords":205,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":94},"100529329","phase-3-induction-and-tapering-therapy-with-tofacitinib-and-glucocorticoid-in-patients-with-polymyalgia-rheumatica-100529329","NCT06172361","Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica","Efficacy and Safety of Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica (ITTG PMR): An Open-label 52-week Randomized Controlled Trial","ITTGPMR","Inclusion Criteria:\n\n1. PMR patients who fulfilled the 1982 Chuang criteria or 2012ACR\u002FEULAR criteria for PMR; They did not receive any glucocorticoids or biological agents during the 2 weeks period that preceded their inclusion in the study;\n2. Patients with high activity rheumatic polymyalgia: disease activity score PMR-AS (Table 3) \\> 10,\n3. Adults age 50-88, Weight 45-85Kg,\n4. ESR\\>20mm\u002Fh or CRP \\>50mg\u002FL (5mg\u002Fdl),\n5. Informed consent.\n\nExclusion Criteria:\n\n1. Patients with known allergies to tofacitinib, prednisone or methylprednisolone,\n2. Patients with identified giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis, calcium pyrophosphate deposition (CPPD) arthropathy, and other rheumatic diseases,\n3. Patients with severe osteoarthritis,\n4. Subjects with any severe acute, chronic or recurrent infection (e.g. pneumonia or pyelonephritis, recurrent pneumonia, chronic bronchiectasis, tuberculosis, etc.),\n5. Hepatitis B virus carriers or individuals with chronic active hepatitis B or C, other chronic liver diseases, HIV infection,\n6. Patients with abnormal liver function (ALT\u002FAST 2 times higher); Moderate to severe renal impairment (glomerular filtration rate \\\u003C60); hyperlipidemia not improved by lipid-lowering drugs,\n7. Pregnant or lactating women,\n8. Patients with a history of malignancy who do not meet the following condition (patients with malignant tumors who have been successfully treated for more than 5 years before screening without any evidence of recurrence),\n9. Patients with previous visual field disorder or single eye dysfunction, cataract patients,\n10. Patients with decompensated cardiac insufficiency or severe hypertension or diabetes mellitus, i.e. systolic blood pressure higher than 160mmhg or diastolic blood pressure higher than 100mmhg,\n11. For patients with abnormal blood routine, lymphocytes \\\u003C500\u002Fmm3 or ANC \\\u003C1000\u002Fmm3 or HGB \\\u003C 90g\u002FL,\n12. Patients with active bleeding and peptic ulcer,\n13. Have used biological agents or added azathioprine, leflunomide, FK 506 within 1 month before enrollment,\n14. Those who have participated in other drug clinical trials within 4 weeks,\n15. Patients using CYP3A4 inhibitors or inducers such as ketoconazole, fluconazole, or rifampicin within 4 weeks.","88 Years",{"count":200,"type":20},98,[202],"PHASE3","This will be efficacy and safety of Induction and Tapering Therapy with Tofacitinib and Glucocorticoid in patients with Polymyalgia Rheumatica (ITTG PMR): An open-label 52-week randomized controlled trial",[26],[26,206,207],"Tofacitinib","Glucocorticoid","2025-08-11",{"date":210,"type":31},"2025-08-13",{"date":212,"type":31},"2024-01-20",{"date":214,"type":20},"2026-01-30",{"name":216,"class":66},"Zhejiang University",{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":131,"sex":16,"minAge":74,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":94},"100551442","assessing-biomarker-in-giant-cell-arteritis-and-polymyalgia-rheumatic-100551442","NCT06460142","Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic","Multimodal Assessment of Biomarkers for Diagnosing Giant Cell Arteritis and Polymyalgia Rheumatica: A Comprehensive Analysis of Clinical, Laboratory, and Imaging Profiles","GCAIO","Inclusion Criteria:\n\n* Informed Consent: Participants (\\>18 years) must provide written informed consent to voluntarily participate in the study.\n* Confirmed Diagnosis: Diagnosis of GCA or PMR confirmed by the treating physician and fulfilling expanded ACR-EULAR classification criteria. Patients must have been either newly diagnosed within the last three days or have experienced a disease flare within the same timeframe.\n\nExclusion Criteria:\n\n* Severe Renal Insufficiency: Chronic glomerular filtration rate (GFR) less than 30 mL\u002Fmin.\n* Other Medical Conditions Requiring Glucocorticoids: Presence of medical conditions other than GCA or PMR that necessitate continuous or intermittent treatment with oral or parenteral glucocorticoids.\n* Other Inflammatory Rheumatic Diseases: Patients with other inflammatory rheumatic diseases.",{"count":226,"type":20},100,"The GCAIO study is an innovative, multimodal research initiative designed to enhance the understanding, diagnosis, and management of giant cell arteritis (GCA) and frequently associated polymyalgia rheumatica (PMR). This longitudinal study aims to dissect the complex immunological landscape and systemic manifestations of these conditions through a combination of diagnostic imaging and detailed immunological profiling.\n\nThe study focuses on three primary objectives: (1) Identifying and analyzing cytokine profiles and immune cell phenotypes, employing techniques like flow cytometry, enzyme-linked immunosorbent assays (ELISA), and next-generation sequencing to predict disease activity and therapeutic responses. (2) Advancing diagnostic and monitoring capabilities through the application of novel and established imaging technologies, including MRI, optical coherence tomography angiography (OCTA), and ultrasound. These modalities aim to improve the detection of neuro-ophthalmological, cardiac, and aortic complications in GCA, potentially offering more precise monitoring and earlier diagnosis. (3) Enhancing the understanding of PMR within the context of GCA by exploring specific biomarkers and advanced imaging to refine diagnostic accuracy and treatment strategies, thus improving patient outcomes.",[109,26],[109,26,230,231,232,233,234,235,236,237,238,239,240,241,242,243,244],"Vasculitis","Inflammatory Disorders","Clinical Biomarkers","Predictive Biomarkers","Disease Activity Monitoring","Therapeutic Response","Diagnostic Imaging Techniques","Aortic Imaging","Magnetic Resonance Imaging (MRI)","Vascular Ultrasound","Optical Coherence Tomography Angiography (OCT-A)","Transcriptome Analysis","Vascular-adhesion protein 1","Positron emission tomography-computed tomography (PET\u002FCT)","Siglec-9","2025-04-07",{"date":247,"type":31},"2025-04-10",{"date":249,"type":31},"2023-09-01",{"date":251,"type":20},"2027-09-30",{"name":253,"class":66},"University of Bonn",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":263,"studyType":50,"phases":4,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":272,"locationsCount":274},"100370406","clinical-and-immunogenetic-characterization-of-giant-cell-arteritis-gca-and-polymyalgia-rheumatica-pmr-100370406","NCT04102930","Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)","UK GCA Consortium: Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)","Inclusion Criteria:\n\n* Willing to self-identify an ethnic group, such as Caucasian, Asian, Afro-Caribbean.\n* Have a firm clinical diagnosis of GCA or PMR, or (for patients identified prospectively) GCA or PMR should be more likely than any alternative explanation for the patient's symptoms.\n* Able and willing to give informed consent. Patients will be 50 years of age or over, unless both biopsy-proven and a clinically classical case of GCA.\n\nExclusion Criteria:\n\n• Patient unwilling or unable to give fully informed consent.",{"count":262,"type":20},4500,"18 Months","A multi-centre observational study recruiting prospective and retrospective cohorts of patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). The primary aim is to find genetic determinants of GCA and PMR susceptibility, in order to yield novel insights into disease pathogenesis. A subset of the retrospective cohort is also enrolled in a post-marketing surveillance registry of patients eligible for, or receiving tocilizumab, to treat their relapsing or refractory GCA.",[109,26],"2025-03-25",{"date":268,"type":31},"2025-03-30",{"date":270,"type":31},"2005-06-10",{"date":91,"type":20},{"name":273,"class":66},"University of Leeds",76,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":135,"studyType":50,"phases":4,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":189},"100511151","danish-vasculitis-database-danivas-100511151","NCT05935709","DANIsh VASculitis Database (DANIVAS)","Disease Stratification in GCA and PMR to Inform Management and Reduce Disease and Treatment-related Damage","DANIVAS","Inclusion Criteria:\n\n* Are diagnosed with GCA or PMR within the last 5 years\n* Diagnosis is established by or confirmed by a rheumatologist (clinical expert opinion)\n* Speak and understand Danish\n* Are able to give signed and dated informed consent\n\nExclusion Criteria:\n\n* Denies or are not able to give informed consent\n* Are diagnosed with other systemic autoimmune diseases that out-rules the diagnosis of GCA or PMR",{"count":284,"type":20},3000,"The aim of this national pragmatic observational study is to investigate whether the use of new diagnostic imaging modalities facilitates disease stratification that can potentially predict treatment response, relapse risk and complications and hence guide management strategies to improve disease control and reduce disease and treatment related damage.",[109,26],"2024-01-22",{"date":289,"type":31},"2024-01-24",{"date":291,"type":31},"2023-11-10",{"date":293,"type":20},"2051-12-31",{"name":295,"class":66},"Aarhus University Hospital"]